Abstract
Evaluation of: Elia L, Aurisicchio L, Facciabene A et al. CD4+CD25+ regulatory T-cell inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. DOI: 10.1038/sj.cgt.7701004 (2006) (Epub ahead of print).Numerous cancer vaccine clinical trials have been carried out using various antigen-delivery systems and adjuvants. However, the therapeutic outcomes in patients have been minimal. There are numerous reasons for this and one of the current hypotheses is the inhibitory effects of regulatory T cells (Treg) on T-cell effectors. Since most tumor antigens are self antigens, antitumor responses to these antigens are dampened by Treg that are present to prevent autoreactive T cells from damaging healthy tissue. The paper by Elia and colleagues describes an alternative strategy to overcome the suppressive effects of Treg cells and generate enhanced cellular responses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
